TY - JOUR
T1 - A genome-wide association and admixture mapping study of bronchodilator drug response in African Americans with asthma
AU - Spear, Melissa L.
AU - Hu, Donglei
AU - Pino-Yanes, Maria
AU - Huntsman, Scott
AU - Eng, Celeste
AU - Levin, Albert M.
AU - Ortega, Victor E.
AU - White, Marquitta J.
AU - McGarry, Meghan E.
AU - Thakur, Neeta
AU - Galanter, Joshua
AU - Mak, Angel C.Y.
AU - Oh, Sam S.
AU - Ampleford, Elizabeth
AU - Peters, Stephen P.
AU - Davis, Adam
AU - Kumar, Rajesh
AU - Farber, Harold J.
AU - Meade, Kelley
AU - Avila, Pedro C.
AU - Serebrisky, Denise
AU - Lenoir, Michael A.
AU - Brigino-Buenaventura, Emerita
AU - Cintron, William Rodriguez
AU - Thyne, Shannon M.
AU - Rodriguez-Santana, Jose R.
AU - Ford, Jean G.
AU - Chapela, Rocio
AU - Estrada, Andrés Moreno
AU - Sandoval, Karla
AU - Seibold, Max A.
AU - Winkler, Cheryl A.
AU - Bleecker, Eugene R.
AU - Myers, Deborah A.
AU - Williams, L. Keoki
AU - Hernandez, Ryan D.
AU - Torgerson, Dara G.
AU - Burchard, Esteban G.
N1 - Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Short-acting β2-adrenergic receptor agonists (SABAs) are the most commonly prescribed asthma medications worldwide. Response to SABAs is measured as bronchodilator drug response (BDR), which varies among racial/ethnic groups in the United States. However, the genetic variation that contributes to BDR is largely undefined in African Americans with asthma. To identify genetic variants that may contribute to differences in BDR in African Americans with asthma, we performed a genome-wide association study (GWAS) of BDR in 949 African-American children with asthma, genotyped with the Axiom World Array 4 (Affymetrix, Santa Clara, CA) followed by imputation using 1000 Genomes phase III genotypes. We used linear regression models adjusting for age, sex, body mass index (BMI) and genetic ancestry to test for an association between BDR and genotype at single-nucleotide polymorphisms (SNPs). To increase power and distinguish between shared vs. population-specific associations with BDR in children with asthma, we performed a meta-analysis across 949 African Americans and 1830 Latinos (total = 2779). Finally, we performed genome-wide admixture mapping to identify regions whereby local African or European ancestry is associated with BDR in African Americans. We identified a population-specific association with an intergenic SNP on chromosome 9q21 that was significantly associated with BDR (rs73650726, p = 7.69 × 10−9). A trans-ethnic meta-analysis across African Americans and Latinos identified three additional SNPs within the intron of PRKG1 that were significantly associated with BDR (rs7903366, rs7070958 and rs7081864, p ≤ 5 × 10−8). Our results failed to replicate in three additional populations of 416 Latinos and 1615 African Americans. Our findings indicate that both population-specific and shared genetic variation contributes to differences in BDR in minority children with asthma, and that the genetic underpinnings of BDR may differ between racial/ethnic groups.
AB - Short-acting β2-adrenergic receptor agonists (SABAs) are the most commonly prescribed asthma medications worldwide. Response to SABAs is measured as bronchodilator drug response (BDR), which varies among racial/ethnic groups in the United States. However, the genetic variation that contributes to BDR is largely undefined in African Americans with asthma. To identify genetic variants that may contribute to differences in BDR in African Americans with asthma, we performed a genome-wide association study (GWAS) of BDR in 949 African-American children with asthma, genotyped with the Axiom World Array 4 (Affymetrix, Santa Clara, CA) followed by imputation using 1000 Genomes phase III genotypes. We used linear regression models adjusting for age, sex, body mass index (BMI) and genetic ancestry to test for an association between BDR and genotype at single-nucleotide polymorphisms (SNPs). To increase power and distinguish between shared vs. population-specific associations with BDR in children with asthma, we performed a meta-analysis across 949 African Americans and 1830 Latinos (total = 2779). Finally, we performed genome-wide admixture mapping to identify regions whereby local African or European ancestry is associated with BDR in African Americans. We identified a population-specific association with an intergenic SNP on chromosome 9q21 that was significantly associated with BDR (rs73650726, p = 7.69 × 10−9). A trans-ethnic meta-analysis across African Americans and Latinos identified three additional SNPs within the intron of PRKG1 that were significantly associated with BDR (rs7903366, rs7070958 and rs7081864, p ≤ 5 × 10−8). Our results failed to replicate in three additional populations of 416 Latinos and 1615 African Americans. Our findings indicate that both population-specific and shared genetic variation contributes to differences in BDR in minority children with asthma, and that the genetic underpinnings of BDR may differ between racial/ethnic groups.
UR - http://www.scopus.com/inward/record.url?scp=85053560689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053560689&partnerID=8YFLogxK
U2 - 10.1038/s41397-018-0042-4
DO - 10.1038/s41397-018-0042-4
M3 - Article
C2 - 30206298
AN - SCOPUS:85053560689
SN - 1470-269X
VL - 19
SP - 249
EP - 259
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
IS - 3
ER -